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Use of highly active antiretroviral
therapy (HAART) has remained the only regimen
potent enough to reduce viral replication in HIV-
infected individuals. Its combination with co-
trimoxazole has also been recommended in those
with CD4% of less than 15%. The use of HAART
containing zidovudine (ZDV) in combination with
co-trimoxazole carries the risk of anaemia in
already anaemic predisposed individuals from HIV
infections, opportunistic infections, parasitic
infestations, sickle cell anaemia, and malnutrition.
The aim of the study is to document the effect of use
of combination of HAART containing ZDV with co-
trimoxazole in haemoglobin profile of HIV-infected
children after one year of its administration at the
University of Abuja Teaching Hospital (UATH),
Gwagwalada. It is also aimed at comparing the
result obtained with those on stavudine containing
HAART with co-trimoxazole.
A two year prospective study of HIV-
infected children on treatment with HAART in
combination with co-trimoxazole, and attending
the paediatric outpatient special treatment clinic
(POSTC) for HIV infected children at the UATH,
Gwagwalada from November 2006 to October
2008, was carried out to determine effect of these
drug combinations in the haemoglobin profile of
infected children. Three monthly PCV level was
carried out using haematocrit centrifuge and
reader.
A total of 173 patients were started on
HAART during the first year recruitment period, 90
(52.0%) were males, while 83 (48.0%) females,
giving a male to female ratio of 1.1:1. One hundred
and seventeen (67.7%) of patients were on ZDV
containing HAART, while 56 (32.3%) were on
stavudine containing combination.
All patients were started on co-trimoxazole
prophylaxis with the exception of 6 (3.5%) patients
because of drug reaction. The mean PCV of
patients on ZDV containing combination with co-
trimoxazole decreased from 30.2 ± 5.5% to 29.0 ±
2.3%, with a net decrease of 1.2% after one year
treatment, those on stavudine containing
combination with co-trimoxazole instead showed
an increased from initial PCV of 28.3 ± 4.2% to 34.2
± 3.0% with a net increase of 5.9% after the same
duration of treatment, ( p>0.05). While patients
on ZDV combination alone without co-trimoxazole
prophylaxis had a minimal decrease of 0.9% in
their PCV level after one year treatment, those on
stavudine combination alone without any
prophylaxis instead showed an increase of 6.8% in
their PCV after the same duration of treatment.
A combination of HAART containing
ZDV plus co-trimoxazole carries risk of anaemia
than that of stavudine containing combination
with co-trimoxazole. Such combination should
therefore not be given to anaemic patients.
Regular check in PCV of patients on HAART
combination with ZDV and additional co-
trimoxazole prophylaxis is required for early
detection of significant drop in PCV level.
Highly active antiretroviral therapy,
zidovudine, stavudine, co-trimoxazole, anaemia.
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Introduction
Anaemia is a common condition in HIV infected
children and contributes significantly to its
morbidity and mortality. Its prevalence is
determined to a large extent to the prevailing
conditions that cause anaemia in the environment
like malaria, sickle cell anaemia, helminthiasis,
malnutrition and micro-nutrient deficiencies.
The basic pathology in the anaemia of HIV infection
appears to be related to the release of
inflammatory cytokines during the chronic disease
process which not only inhibits erythropoiesis by
blunting the erythropoietin response, but also
reduces the red blood cell survival via the haemo-
phagocytic mechanism as well as preventing the
release of iron from the reticuloedothelial system.
Despite the survival benefits of antiretroviral drugs
(ARD) in patients living with HIV, the clinical
management of the disease presents a major
challenge for both clinicians and patients.
Treatment of HIV infection with ARD is aimed at
preventing progression of the disease to AIDS and
death by reducing the plasma HIV ribonucleic acid
(RNA) to as low levels as possible. The
eradication of HIV from an individual is not
considered possible with the a single ARD, and
people undergoing treatment for HIV disease must
take a daily regimen of at least three ARD
combinations otherwise known as highly active
antiretroviral therapy (HAART).
HAART is the only regimen potent enough to
drastically reduce viral replication, prevent the
emergence of resistance, restore immune status,
slows HIV disease progression, has durable
therapeutic responses, improve quality of life and
promotes normal growth and development in
children. Zidovudine or stavudine is commonly
paired with lamivudine or abacavir as the
nucleoside components of HAART regimen.
Zidovudine is well known for its bone marrow
suppressive effect. The suppression being
related to marrow reserve, dosage of the drug,
duration of treatment and the stage of HIV
disease. Anaemia is one of the major bone
marrow suppressive effect of ZDV and is commonly














HIV infected children are saddled with problem of
opportunistic infections for which co-trimoxazole
( c o m b i n a t i o n o f t r i m e t h o p r i m a n d
sulphametoxazole ) is commonly given as
prophylaxis. The trimethoprim component of co-
trimoxazole is an anti-foliate metabolite that
inhibits the enzymic reduction of folate to folinic
acid via the dihydro-reductase pathway. This
inhibitory process eventually leads to loss of
pur ine and hence poor synthes i s of
deoxyribonucleic acid (DNA) in the human cell,
with subsequent megaloblastic changes in the
marrow and manifestation of megaloblastic
anaemia.
This singular effect is expected to worsen the
anaemia of patients on ZDV. Thus HIV infected
children in this environment and on treatment
with HAART containing ZDV plus co-trimoxazole,
are saddled with problems of anaemia from
nutritional causes, micro-nutrient deficiencies,
c h r o n i c H I V d i s e a s e a n d o t h e r
infect ions/ infestat ions , bone marrow
suppressive effect of ZDV, as well as anti-folate
activity of co-trimoxazole. The aim of the present
study is to document the prevalence of anaemia
in HIV/AIDS in children on treatment with HAART.
It is also aimed at determining the effect of
HAART containing ZDV plus co-trimoxazole on
haemoglobin profile of infected children, and
comparing the result with those on HAART
containing stavudine (whose major side effect is
not anaemia) plus co-trimoxazole.
The prospective study was conducted at the
paediatric outpatient special treatment clinic
(POSTC) for HIV/AIDS children at the UATH,
Gwagwalada over a two year period, from
November 2006 to October 2008. The subjects
were paediatric HIV/AIDS patients on HAART with
or without co-trimoxazole. Patients were aged
between two months to 15 years and positive for
HIV infection either by serology method or by
deoxyribonucleic acid (DNA) polymerase chain
reaction (PCR) test. For children 18 months of age
and above, the sera were screened for the
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available recombinant antigen based double rapid
test (STATPAK by Chembio-Diagnostic System Inc,
New York, and DETERMINE by Abbot laboratories
Japan), with sensitivity and specificity of 100%. For
those less than 18 months of age diagnosis was
based on use of DNA PCR test. DNA PCR test
amplifies and detects the HIV pro-viral DNA
sequences within the mono-nuclear cells in the
blood, and is 100% sensitive after 4 to 6 weeks of
life.
Blood for PCV was collected for all patients by the
medical officer attached to the POSTC at
recruitment, and subsequently at a three monthly
intervals for the one year follow up period. Samples
were collected at the dorsum of the right or left
hand with 5 ml syringe after wiping the area with 2%
alcohol spirit swab. The collected sample was
centrifuged using a haematocrit centrifuge
(Hawksley micro-haematocrit centrifuge, made in
England by Hawksley & sons Limited) at 2,000
rovers per minute for 5 minutes. The PCV value was
read with haematocrit reader (Hawksley micro-
haematocrit reader).
Information collected at recruitment includes age
of the patient, sex and body weight. CD4 cell count
and its percentage, WHO clinical staging of the
patients and their intial PCV level were also
collected at recruitment. First line HAART regimens
used for the patients were combinations of ZDV or
stavudine plus lamivudine and nevirapine (NVP) or
efevarenz (EFZ) depending on whether the patient
was receiving anti-tuberculous therapy. Those on
anti-tuberculous medication with rifampicin were
given EFV instead of NVP when age is greater than 3
years or weight >10kg. When age is less than 3 years
or weight <10kg, NVP was replaced with abacavir.
Second line HAART regimen used were combination
of ZDV or stavudine, plus lamivudine and lopinavir/
ritonavir.
University of Abuja Teaching Hospital is a 350 bed
capacity referral centre sub serving FCT and
neighbouring states like Nassarawa, Kogi, Benue,
Niger, and parts of Kaduna. It is one of the centers in
the country that offers free medical services to
HIV/AIDS patients courtesy of United State
government.
6
The study was carried out after approval from the
ethics committee of the hospital, and informed
written down consent obtained from the
parents/ guardian of the patients following
explanation on the implication of the study, in the
language they understands most.
Paediatric patients who met the World Health
Organization (WHO)/ National guideline for
paediatric HIV and AIDS commencement on
HAART were started on the drugs. They include
patients greater than 3 years whose CD4 cell
percentage were less than 15%, those between 1-
3 years with CD4 percentage of less than 20%,
and those less than one year whose CD4
percentage is less than 25%.
All infected infants, older children with
symptomatic HIV disease or an AIDS defining
illness or those with CD4 of less than 20% for age
1-3years, or less than 15% for older children were
all started on co-trimoxazole prophylaxis. On
recruitment of patients which lasted for one year,
clinical, immunological and haematological
assessments were carried out. This included
general physical examination, anthropometric
measurements (body weight, recumbent length
o r h e i g ht a n d h e a d c i rc u m fe re n c e ) ,
immunological assessment (CD4 cell count and
its percentages), haematological profile (full
blood count and differential, packed cell volume),
and blood chemistry (liver function test,
urea/creatinine, and lipid profile).
For the purpose of the study, the patients were
grouped into four based on the type of
nucleoside reverse transcriptase inhibitors
(NRTIs) component of HAART used, the PCV
results at recruitment, as well as use or non- use
of co-trimoxazole prophylaxis. The summary of
the groups were as follows:
- HAART (ZDV) patients without co-
trimoxazole.
- HAART (ZDV) with co-trimoxazole.
- HAART (stavudine) patients without
co-trimoxazole.
– HAART (stavudine) with co-
trimoxazole.
Patients were assigned to ZDV or stavudine group
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When PCV was found to be greater than 30%,
patients were assigned to ZDV group, but when less
than 30% they will be assigned to stavudine group.
30% PCV level was chosen because this is the level
that signifies moderate anaemia. Patients with
moderate to severe anaemia were not assigned to
ZDV group because of possibility of ZDV worsening
the anaemia from its bone marrow suppressive
effect. They were instead assigned to stavudine
group. Because all infants were expected to be on
co-trimoxazole prophylaxis irrespective of CD4 cell
count and its percentage, they were not assigned to
groups 1 & 111. Data entry and analysis was carried
out using SPSS programme version 7.5 that
provided frequency distribution, means, standard
deviations, and correlation coefficient.
A total of 173 patients were stared on HAART
during the one year recruitment period, 90 (52.0%)
were males and 83 (48.0%) females giving a male to
female ratio of 1.1:1. One hundred and sixty seven
(167) of 173 recruited patients (96.5%) were on co-
trimoxazole prophylaxis, while 6 (3.5%) were not
because of drug reaction, and alternative drug
(dapsone) was used instead. Significant number of
recruited patients 117 (67.6%) were also on ZDV
combination as against 56 (32.3%) on stavudine (p<
0.05). Of the 117 patients on ZDV, 113 (96.6%) were
also on additional co-trimoxazole prophylaxis, 4
(3.4%) were not, and of the 56 patients on
stavudine, 54 (96.4%) were on co-trimoxazole,
while 2 (3.6%) were not.
The mean age of the patients at recruitment was
4.1 ± 1.2 years, while there mean CD4 cell count,
CD4 percentage and WHO clinical staging were
216.9 ± 104.2cells/ml, 11.7%, and stages 3
respectively, all signifying advanced immune
suppression at recruitment, (table I). Table II shows
WHO clinical staging and PCV values of recruited
patients.A total of 56/173 (32.4%) of the patients
were at WHO stage 4, 83/173 (48.0%) in stage 3,
34/173 (19.7%) in stage 2 disease, and none in
asymptomatic stage 1. When compared to stage 2
patients, there is a statistical significant difference
between their mean PCV and that of stage 4




There was also statistical significant difference
between mean PCV of stage 2 and stage 3 disease
(35.0% Vs 32.3%, p = 0.034). It was also noted that
18/56 (32.1%) of patients in stage 4, 12/83
(14.5%) in stage 3, 2/34 (5.9%) in stage 2
presented with PCV of less than 21% signifying
severe anaemia. There is a positive correlation
between the level of PCV and the degree of
immune suppression ( r=0.48, p=0.06).
Table 111 shows the changes in PCV level during
one year treatment with different regimen of
HAART. While there was a net increase in PCV of
6.8% from a baseline value of 28.3% to 35.1%
after one year treatment for those on stavudine
containing HAART without co-trimoxazole,
patients on ZDV containing combination without
co-trimoxazole prophylaxis had a slight decrease
in PCV value from 30.5% to 29.6%, (0.9%). The
sample size of the two groups were however too
small for any meaningful statistical comparism (4
and 2 respectively).
When compared with stavudine containing
HAART plus co-trimoxazole, and ZDV containing
HAART with co-trimoxazole, that of ZDV group
with co-trimoxazole showed a non significant
decrease in PCV value from 30.2±5.5 to 29.0±2.3,
(1.2% decrease), p>0.05, after one year
treatment, while that of stavudine with co-
trimoxazole instead showed a significant increase
from 28.3±4.2 to 34.2±3.0, (5.9% increase), p<
0.01. In summary, while there was a net decrease
in PCV value of 1.2% in ZDV group with co-
trimoxazole, stavudine combination with co-
trimoxazole showed an increase of 5.9%, p< 0.05
It is also obvious from the data that while patients
on only ZDV containing HAART without co-
trimoxazole prophylaxis showed a minimal
decrease in their PCV (0.9%) after one year of
treatment, those in the same regimen with
additional co-trimoxazole prophylaxis instead
showed a decrease in their PCV (1.2%), after the
same duration of treatment. In the same vain, the
increase in PCV for patients on stavudine
containing HAART alone without co-trimoxazole
was higher (6.8%), while those on stavudine
containing regimen with co-trimoxazole had an
increase of 5.9%.
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Six patients died in the first year recruitment phase,
two of which was from severe pneumonia, two
from severe jaundice with positive antibody to
hepatitis B surface antigen, one from HIV
encephalopathy, and the remaining one from
severe anaemia with septicemia. An additional two
patients died during the second year from severe
malaria and meningitis, making a total of 8 patients,
with a mortality of 4.6%. At the end of the study,
150 patients (86.7%) were alive and on first line
anti retroviral treatment, 3 (1.7%) were alive and
on second line drugs, 10 (5.7%) were lost to follow
up, while 2 (1.2%) discontinued ARD, as a result of
adherence failure following several serious
counseling sessions.
Table I : Characteristics of Recruited Patients
Variables M F Total (%)















Group 11 61 52 113 (65.3)
Group111 1 1 2 (1.7)













CD4 cell count (cells/ml) *209.7 ±104.2 228.2 ± 109.7 216.7 ± 104.2
% CD4 cell count *11.4 *11.9 *11.7
PCV % *30.0 *28.6 *29.3
*Values are means ± STD.
PCV – Packed Cell Volume.
WHO- World Health Organisation.
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1. 0(0.0) 00.0 0/0 (0.0) 0.0
2. 34 (19.7) 35.0 2/34 (5.9) 3.2±1.6
3. 83 (48.0) 32.3 12/83 (14.5) 4.7±1.1
4. 56 (32.4) 20.7 18/56 (32.1) 4.3±0.6
Table III: Packed Cell Volume Changes during One Year Treatment on HAART.







HAART 173 29.3 ± 5.0 31.5 ± 4.7 32.0 ± 6.2
Group 1 4 30.5 ± 5.7 31.0 ± 3.4 29.6 ± 3.5
Group 11 101 30.2 ± 5.5 31.2 ± 4.1 29.0 ± 2.3
Group 111 2 28.3 ± 4.2 32.1 ± 6.0 35.1 ± 4.9
Group 1V 47 28.3 ± 4.2 31.6 ± 5.9 34.2 ± 3.0
HAART – Highly Active Antiretroviral Therapy
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Discussion
Anaemia is a common manifestation of HIV
infection in children. This is evident in this study
where 129/173 ( 74.6%) of the patients seen
presented with mild to moderate anaemia, (PCV of
less than 30%), 32/173 (18.5%) with features of
severe anaemia, (PCV of less than 21%), and 12/173
(6.9%) with no features of anaemia. The findings
were similar with reports from Jos (73.7%) and
South Africa (72.0%). The high prevalence of
anaemia seen in HIV infected children in the
present and other studies is to a large extent not
only due to both direct and indirect effect of HIV
infection on erythropioesis, but also as a result
excessive destruction, erythropoietic factor
deficiencies, and other co-existing disease
conditions as highlighted in the introductory part of
this article. The incidence of anaemia in HIV disease
is dependent on the severity of HIV disease as well
as the level of haemoglobin.
In a survey by the Centre for Disease Control (CDC)
in the United State of America (USA), among 3,200
adolescents and adults with HIV infection and on
treatment with the ARD, the prevalence of
moderate anaemia with Hb of <10g/dL was found
to be 31.6% in patients with CD4 cell count of
<200cells/ml, and 4.5% in those with cells of
>200cells/ml. The same study showed prevalence
of mild to moderate anaemia of Hb of 10-14g/dL to
be present in 31.3% of patients with AIDS and
26.6% in those without AIDS. The present study
noted severe anaemia of PCV of < 21% to be
present in 32.1% of WHO stage 4 disease of severe
immune suppression, and 5.9% in those in stage 2
of mild to moderate immune suppression.
This findings appears similar with CDC survey
among adolescents and adults population, but
appeared much lower than the report from South
African were severe anaemia of PCV of <21% was
found to be present in 92%, and 76% of patients
with severe and moderate immune suppression. All
these findings highlights not only the significant
relationship between immunological status of HIV
patients and their Hb level, but also the adverse










In addition to the adduced reasons highlighted
previously as the causes of high prevalence of
anaemia in HIV infected individuals, which
worsen as the disease progresses, the parvovirus
B19 induce chronic anaemia in HIV infected may
also be an additional factor. HIV infected
individual with severe immune suppression lacks
the ability to mount antibody against the
structural proteins of B19 parvovirus, a well
known cause of severe anaemia in immune
compromised individuals.
Zidovdine, stavudine and lamivudine are the
nucleotide reverse transcriptase inhibitors
(NRTIs) component of HAART used in this study.
They act by incorporating themselves into the
DNA of HIV virus formed, thus stopping the
building process and formation of the new
virus. Bone marrow suppression is a known
and major side effect of ZDV, suppression being
related to the marrow reserve, dosage of the
drug, duration of treatment and stage of HIV
disease. Stavudine is noted for its peripheral
neuropathy from mitochondrial toxicity.
Marrow suppression or anaemia is not its major
side effect.
Trimethoprim and sulphametoxazole, are the
two drug combinations in co-trimoxazole used as
prophylaxis against most opportunistic infections
in HIV infected individuals. Both drugs act at two
levels in the biosynthesis of tetra-hydrofolic acid,
a precursor in the synthesis of folic acid and
purine. While sulphametoxazole inhibits the
incorporation of para-amino benzoic acid (PABA)
into folic acid, trimethoprim blocks the reduction
of dihydrofolic acid to tetra-hydrofolic acid. All
this processes are needed in the synthesis of folic
acid and purine. Failure of purine and folic acid
synthesis results in megaloblastic changes in the
bone marrow. At the end of one year treatment,
children on HAART containing stavudine had a
higher PCV than those on ZDV containing
combination, even though the latter started off
treatment with higher PCV. This was more
pronounced in patients who received co-
trimoxazole prophylaxis: thus depicting the
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as well as the anti-folate activities of co-
trimoxazole which resulted in a slight drop in PCV
value when ZDV plus co-trimoxazole combination.
A combination of HAART containing ZDV plus co-
trimoxazole carries a greater risk of anaemia than
Conclusion
that of stavudine containing HAART with co-
trimoxazole. Such combinations may not be very
advisable in anaemia patients. . Regular check in
PCV of patients on HAART, especially those
receiving ZDV containing HAART and co-
trimoxazole prophylaxis is required for early
detection of significant drop in PCV level.
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